Skip to main content
Equibles

DRTS · Alpha Tau Medical Ltd. · Metrics

Track DRTS — free

Use DRTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DRTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$13.48 +0.39 (+2.98%) At close · Oct 21
Rebalance outlook locked
Market Cap
$1.25B
Shares
92.48M
Volume · Oct 21 500.36K Avg daily vol (3M) 549.56K

DRTS metrics

60 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$13.48
Market cap
$1.25B

Price action

20 metrics
Price change (1W)
-4.7%
Price change (30D)
-15.5%
Price change (3M)
-1.7%
Price change (6M)
+65.7%
Price change (YTD)
+164.4%
Price change (1Y)
+227.3%
Trailing year
Price change (5Y)
+32.2%
52-week high
$15.50
52-week low
$3.47
Change from 52-week high
-15.5%
Change from 52-week low
+277.2%
Annualized volatility
77.2%
Annualized volatility (3M)
47.3%
Beta
2.1
RSI (14D)
40.1
Price vs SMA 50
-9.3%
Price vs SMA 200
+26.8%
Avg volume (3M)
554,769
Relative volume
1.5
Average dollar volume
$7.75M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
92.48M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
27.5
reciprocal yield 3.6%
FCF yield
-1.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-7.6%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-11

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$50.43M
Net income (TTM)
−$92.57M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.48

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+27.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-210.1%
Return on assets
-69.0%
Debt / equity
0.1
Current ratio
11.1
EBITDA (TTM)
—
Free cash flow (TTM)
−$16.11M
Quick ratio
11.1
Interest coverage
-140.1
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$70.02M
Latest balance sheet
Cash & equivalents
$22.99M
Total assets
$134.25M
Total debt
$6.40M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$12.81M
Capital expenditures (TTM)
$3.30M
R&D (TTM)
$38.77M
SG&A (TTM)
—
Stock compensation (TTM)
$11.99M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
92
13F filer change QoQ
+22
Institutional ownership
14.5%
Conviction holders (share of 13F filers)
1.4%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+99.6%
Holder tenure
4.5
Price vs estimated holder cost
+82.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
3.7%
Latest settlement · 6.6 days to cover
Days to cover
6.6d
Short-squeeze score
59 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$291,350
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1871321 CUSIP M0740A108 13F (30d) 11 filings 11 filers Visit website Investor relations